Clotrimazole Inhibits Growth of Multiple Myeloma Cells in Vitro Via G0/G1 Arrest and Mitochondrial Apoptosis

Overview

Journal Sci Rep

Specialty Science

Date 2024 Jul 4

PMID 38965397

Authors

Yang Song

Hui Zhang

Jie Geng

Haoran Chen

Yang Bo

Xuechun Lu

Affiliations

Soon will be listed here.

Abstract

Patients with multiple myeloma (MM) experience relapse and drug resistance; therefore, novel treatments are essential. Clotrimazole (CTZ) is a wide-spectrum antifungal drug with antitumor activity. However, CTZ's effects on MM are unclear. We investigated CTZ's effect on MM cell proliferation and apoptosis induction mechanisms. CTZ's effects on MM.1S, NCI- H929, KMS-11, and U266 cell growth were investigated using Cell Counting Kit-8 (CCK-8) assay. The apoptotic cell percentage was quantified with annexin V-fluorescein isothiocyanate/7-amino actinomycin D staining. Mitochondrial membrane potential (MMP) and cell cycle progression were evaluated. Reactive oxygen species (ROS) levels were measured via fluorescence microscopy. Expression of apoptosis-related and nuclear factor (NF)-κB signaling proteins was analyzed using western blotting. The CCK-8 assay indicated that CTZ inhibited cell proliferation based on both dose and exposure time. Flow cytometry revealed that CTZ decreased apoptosis and MMP and induced G0/G1 arrest. Immunofluorescence demonstrated that CTZ dose-dependently elevated in both total and mitochondrial ROS production. Western blotting showed that CTZ enhanced Bax and cleaved poly ADP-ribose polymerase and caspase-3 while decreasing Bcl-2, p-p65, and p-IκBα. Therefore, CTZ inhibits MM cell proliferation by promoting ROS-mediated mitochondrial apoptosis, inducing G0/G1 arrest, inhibiting the NF-κB pathway, and has the potential for treating MM.

References

Yadav P, Yadav R, Jain S, Vaidya A . Caspase-3: A primary target for natural and synthetic compounds for cancer therapy. Chem Biol Drug Des. 2021; 98(1):144-165. DOI: 10.1111/cbdd.13860. View

Carneiro B, El-Deiry W . Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol. 2020; 17(7):395-417. PMC: 8211386. DOI: 10.1038/s41571-020-0341-y. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Liu J, Hong M, Li Y, Chen D, Wu Y, Hu Y . Programmed Cell Death Tunes Tumor Immunity. Front Immunol. 2022; 13:847345. PMC: 9005769. DOI: 10.3389/fimmu.2022.847345. View

Wong A, Shin E, Tergaonkar V, Chng W . Targeting NF-κB Signaling for Multiple Myeloma. Cancers (Basel). 2020; 12(8). PMC: 7463546. DOI: 10.3390/cancers12082203. View

Moreau P, Kumar S, San Miguel J, Davies F, Zamagni E, Bahlis N . Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol. 2021; 22(3):e105-e118. DOI: 10.1016/S1470-2045(20)30756-7. View

Schuler J, Falls Z, Mangione W, Hudson M, Bruggemann L, Samudrala R . Evaluating the performance of drug-repurposing technologies. Drug Discov Today. 2021; 27(1):49-64. PMC: 10014214. DOI: 10.1016/j.drudis.2021.08.002. View

Hernansanz-Agustin P, Enriquez J . Generation of Reactive Oxygen Species by Mitochondria. Antioxidants (Basel). 2021; 10(3). PMC: 8001687. DOI: 10.3390/antiox10030415. View

Zinatizadeh M, Schock B, Chalbatani G, Zarandi P, Jalali S, Miri S . The Nuclear Factor Kappa B (NF-kB) signaling in cancer development and immune diseases. Genes Dis. 2021; 8(3):287-297. PMC: 8093649. DOI: 10.1016/j.gendis.2020.06.005. View

10.

Wang J, Jia L, Kuang Z, Wu T, Hong Y, Chen X . The in vitro and in vivo antitumor effects of clotrimazole on oral squamous cell carcinoma. PLoS One. 2014; 9(6):e98885. PMC: 4043897. DOI: 10.1371/journal.pone.0098885. View

11.

Usha T, Middha S, Kukanur A, Shravani R, Anupama M, Harshitha N . Drug Repurposing Approaches: Existing Leads For Novel Threats And Drug Targets. Curr Protein Pept Sci. 2020; . DOI: 10.2174/1389203721666200921152853. View

12.

Rasmi R, Sakthivel K, Guruvayoorappan C . NF-κB inhibitors in treatment and prevention of lung cancer. Biomed Pharmacother. 2020; 130:110569. DOI: 10.1016/j.biopha.2020.110569. View

13.

Soleimani A, Rahmani F, Ferns G, Ryzhikov M, Avan A, Hassanian S . Role of the NF-κB signaling pathway in the pathogenesis of colorectal cancer. Gene. 2019; 726:144132. DOI: 10.1016/j.gene.2019.144132. View

14.

Jelic M, Mandic A, Maricic S, Srdjenovic B . Oxidative stress and its role in cancer. J Cancer Res Ther. 2021; 17(1):22-28. DOI: 10.4103/jcrt.JCRT_862_16. View

15.

Martinez-Alonso D, Malumbres M . Mammalian cell cycle cyclins. Semin Cell Dev Biol. 2020; 107:28-35. DOI: 10.1016/j.semcdb.2020.03.009. View

16.

Adinolfi B, Carpi S, Romanini A, Da Pozzo E, Castagna M, Costa B . Analysis of the Antitumor Activity of Clotrimazole on A375 Human Melanoma Cells. Anticancer Res. 2015; 35(7):3781-6. View

17.

Ochioni A, Imbroisi Filho R, Esteves A, Leandro J, Demaria T, Nascimento Junior J . Clotrimazole presents anticancer properties against a mouse melanoma model acting as a PI3K inhibitor and inducing repolarization of tumor-associated macrophages. Biochim Biophys Acta Mol Basis Dis. 2021; 1867(12):166263. DOI: 10.1016/j.bbadis.2021.166263. View

18.

Cortat Y, Nedyalkova M, Schindler K, Kadakia P, Demirci G, Nasiri Sovari S . Computer-Aided Drug Design and Synthesis of Rhenium Clotrimazole Antimicrobial Agents. Antibiotics (Basel). 2023; 12(3). PMC: 10044843. DOI: 10.3390/antibiotics12030619. View

19.

Kroemer G, Galluzzi L, Brenner C . Mitochondrial membrane permeabilization in cell death. Physiol Rev. 2007; 87(1):99-163. DOI: 10.1152/physrev.00013.2006. View

20.

Wang C, Wang W, Wang M, Deng J, Sun C, Hu Y . Different evasion strategies in multiple myeloma. Front Immunol. 2024; 15:1346211. PMC: 10920326. DOI: 10.3389/fimmu.2024.1346211. View